Immunotherapy for Breast Cancer: Part 1

Breastcancer.org Podcast

Content provided by Caroline Durham. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Caroline Durham or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

6y ago 17:52

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on April 01, 2022 06:22 (2y ago). Last successful fetch was on February 28, 2022 07:18 (2y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Dr. Sherene Loi is a medical oncologist who specializes in treating breast cancer. In addition to treating patients, particularly patients diagnosed with HER2-positive breast cancer, she also leads the Translation Breast Cancer Genomics and Therapeutics Laboratory at the Peter MacCallum Cancer Centre in Melbourne, Australia, where she is a professor. Much of her clinical research focuses on investigating new treatments, such as immunotherapy, especially for breast cancers that have become resistant to standard treatments.Listen to the podcast to hear Dr. Loi explain: results from the PANACEA trial, which looked at using the immunotherapy medicine Keytruda (chemical name: pembrolizumab) along with Herceptin to treat Herceptin-resistant, HER2-positive, advanced-stage breast cancer that had high levels of PDL-1, a biomarker that indicates that Keytruda will be effective how an immunotherapy medicine like Keytruda works what tumor-infiltrating lymphocytes (TILs) are and why cancer tumors with high numbers of TILs seem to respond better to immunotherapy side effects of immunotherapy medicines Running time: 17:52

215 episodes

#Science #Medicine #Breast Cancer #Caroline Durham #Health and Well-Being #Podcasting Education